Ivy Leaf and Warfarin Interaction
There is no documented clinical interaction between ivy leaf (Hedera helix) and warfarin in the available evidence, but theoretical concern exists based on in vitro data showing ivy leaf inhibits CYP2C8 and CYP2C19 enzymes—though warfarin is primarily metabolized by CYP2C9, not these enzymes.
Evidence Assessment
The FDA warfarin label 1 provides comprehensive lists of botanicals that interact with warfarin, including those with anticoagulant properties (dong quai, garlic, Ginkgo biloba, ginseng, cranberry), coagulant properties (agrimony, goldenseal, yarrow), and those that decrease warfarin effects (St. John's wort, coenzyme Q10). Notably, ivy leaf (Hedera helix) is not mentioned anywhere in the FDA label's extensive botanical interaction section.
The 2022 AHA guideline on drug interactions with oral anticoagulants 2 similarly does not mention ivy leaf among the numerous drug and botanical interactions discussed.
Mechanistic Considerations
Research shows ivy leaf extract inhibits CYP2C8 and CYP2C19 in vitro 3, with IC50 values of 0.08 mg/mL and 0.58 mg/mL respectively, demonstrating time-dependent inhibition. However, warfarin is primarily metabolized by CYP2C9 (S-warfarin, the more potent enantiomer) and CYP3A4 (R-warfarin) 2. The enzymes inhibited by ivy leaf (CYP2C8 and CYP2C19) are not the primary metabolic pathways for warfarin.
A 2021 in vitro study 4 evaluated 17 medicinal plants for anticoagulant activity but did not include ivy leaf in the tested species. A 2021 systematic review on warfarin interactions with 78 herbs and supplements 5 also does not list ivy leaf among the documented interactions.
Clinical Recommendation
Concurrent use of ivy leaf and warfarin appears safe based on the absence of documented clinical interactions and the lack of mechanistic overlap in metabolic pathways. The FDA label 1 states that "medications of unknown interaction with coumarins are best regarded with caution" and recommends more frequent INR monitoring when starting or stopping such medications.
Practical Management:
- No preemptive warfarin dose adjustment is needed when starting ivy leaf
- Check INR within 3-7 days after initiating ivy leaf therapy as a precautionary measure
- Continue routine INR monitoring thereafter
- Counsel patients to report any unusual bleeding or bruising
Important Caveats:
The lack of standardization in herbal preparations 1 means active ingredient content can vary significantly between products. This variability makes predicting interactions difficult, even when theoretical mechanisms suggest low risk.